BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2036827)

  • 21. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.
    Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V
    Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gamma-interferon and soluble interleukin 2 receptor in tuberculous pleural effusion.
    Kim YK; Lee SY; Kwon SS; Kim KH; Moon HS; Song JS; Park SH
    Lung; 2001; 179(3):175-84. PubMed ID: 11891607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
    Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma.
    Tisi E; Lissoni P; Angeli M; Arrigoni C; Corno E; Cassina E; Ballabio D; Benenti C; Barni S; Tancini G
    Cancer; 1992 May; 69(10):2458-62. PubMed ID: 1314691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome.
    Ambrosetti A; Nadali G; Vinante F; Carlini S; Veneri D; Todeschini G; Morosato L; de Sabata D; Chilosi M; Maggi E
    Cancer; 1993 Jul; 72(1):201-6. PubMed ID: 8508408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum soluble interleukin-2 receptor in eosinophilia.
    Kaito K; Otsubo H; Ogasawara Y; Kimura H; Kurihara E; Koike M; Aiso M; Kobayashi M
    Acta Haematol; 2003; 109(1):23-8. PubMed ID: 12486319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The biological significance of soluble interleukin-2 receptors in solid tumors.
    Lissoni P; Barni S; Rovelli F; Viviani S; Maestroni GJ; Conti A; Tancini G
    Eur J Cancer; 1990 Jan; 26(1):33-6. PubMed ID: 2138475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus.
    Oka M; Hazama S; Takahashi M; Yamamoto K; Abe T; Yoshino S; Hayashi H; Tangoku A
    Hepatogastroenterology; 1999; 46(28):2254-9. PubMed ID: 10521976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The significance of serum levels of soluble interleukin-2 receptor in patients undergoing maintenance hemodialysis.
    Chen X; Li Y; Ding X; Zou J; Shen B; Liu Z; Lv W; Cao X; Xiang F
    Ren Fail; 2020 Nov; 42(1):419-427. PubMed ID: 32401100
    [No Abstract]   [Full Text] [Related]  

  • 30. Soluble interleukin-2 receptors in plasma cell dyscrasias.
    Takamatsu T; Yasuda N; Ohno T; Kanoh T; Uchino H; Fujii H
    Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):749-55. PubMed ID: 2618549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer.
    Saito H; Tsujitani S; Ikeguchi M; Maeta M; Kaibara N
    Oncology; 1999 Apr; 56(3):253-8. PubMed ID: 10202282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implication of serum sIL-2R levels in ovarian cancer.
    Wang S; Cai G; Lu Y
    J Tongji Med Univ; 1998; 18(2):126-8. PubMed ID: 10806842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation.
    Grutters JC; Fellrath JM; Mulder L; Janssen R; van den Bosch JM; van Velzen-Blad H
    Chest; 2003 Jul; 124(1):186-95. PubMed ID: 12853522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated serum levels of soluble interleukin-2 receptors in small cell lung carcinoma.
    Yamaguchi K; Nishimura Y; Kiyokawa T; Matsuzaki H; Ishii T; Kubota K; Kawahara M; Furuse K; Yoshinaga T; Kinuwaki E
    J Lab Clin Med; 1990 Oct; 116(4):457-61. PubMed ID: 2170552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
    Dejica D
    Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma.
    Gause A; Roschansky V; Tschiersch A; Smith K; Hasenclever D; Schmits R; Diehl V; Pfreundschuh M
    Ann Oncol; 1991 Feb; 2 Suppl 2():43-7. PubMed ID: 2049320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble interleukin-2 receptor in stage I-III melanoma.
    Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
    Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.
    Srivastava MD; Srivastava A; Srivastava BI
    Leuk Lymphoma; 1994 Jan; 12(3-4):241-51. PubMed ID: 7909467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloid marker S100A8/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity?
    Wieland CW; Vogl T; Ordelman A; Vloedgraven HG; Verwoolde LH; Rensen JM; Roth J; Boer J; Hessels J
    Br J Dermatol; 2013 Jun; 168(6):1252-8. PubMed ID: 23320892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.